CNBC's Meg Tirrell reports the latest on the FDA putting Juno's cancer clinical trial on hold. The "Fast Money" traders weigh in on the biotech sector. » Read More
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
Here's how the Fed could play Grinch and wreck the Santa Claus rally, says Ron Insana.
Jim Cramer rattles off his take on caller favorite stocks, including his warning about this group that could be downhill for the holidays.
U.S. stocks closed mildly lower Thursday as investors awaited Friday's key jobs report that could shed light on the timing of a rate hike.
U.S. stock index futures indicated a higher open on Thursday as traders awaited Friday's key employment report.
The "Halftime Report" traders give their trades ahead of earnings.
Markets will be laser-focused on Friday's October jobs report in the week ahead and may even look past more than a dozen scheduled Fed speeches.
Jim Cramer gives his opinion on caller favorite stocks, including this stock that was recently taken to the woodshed.
Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.
Some biotech stocks may be poised to rise in the days ahead as technical traders step in to buy oversold names in the space.
Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.
Michael Yee, biotech analyst with RBC Capital Markets, says the biotechnology space is still going strong and China-induced volatility will not have any major impact on the sector.
What to buy in biotech
Here's why one market expert is sitting on the sidelines right now, and when he thinks it's a good time to get back in.
It may be down, but today’s action has “Mad Money” host Jim Cramer questioning whether this sector is really out.
Jim Cramer explains that those big pharma and biotech stocks that seem like a safe-haven could be impacted by the troubles in China.
The healthcare secular theme isn't new, but is still very much in force.
Investors are bracing for a bumpy ride after China devalued the yuan by nearly 2 percent. Here are some possible safe stock bets.
AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter.
Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.